Shares of Nano Dimension plunged 14.4% to $1.27 on Monday after the Israeli-born 3D-printing firm unveiled a non-binding term sheet to merge with Infinite Epigenetics, an AI-powered diagnostics startup, in what amounts to a complete reinvention of the business. The stock-for-stock deal values Infinite Epigenetics at $890 million, with Nano shareholders retaining only a minority stake in a combined entity that would operate under the Infinite Epigenetics name and trade on Nasdaq under the proposed ticker "IEAI."

  • Shareholders Are Getting a Minority Seat at a Table They Built. Current Nano Dimension shareholders will hold a minority stake reflecting just a 20% premium over the company's estimated net cash at closing. That cash pile stood at $441.6 million as of March 31, 2026. Meanwhile, Nano's cash per share was $2.11 as of March 2026 — far above today's $1.27 stock price. Investors are being asked to hand that war chest to a pre-revenue diagnostics company valued at nearly $900 million, with no guarantee the premium closes the gap.

  • The Pivot Abandons Everything Nano Was Built On. The merger follows a review of roughly 20 potential opportunities , yet the chosen path ditches industrial 3D printing entirely. Nano already sold its Markforged unit for $42.5 million in late May to reduce cash burn.

Post-merger, Infinite Epigenetics CEO Matthew Dawson — not Nano's current leadership — will run the combined company. Existing shareholders are effectively funding someone else's startup.

  • The Numbers Don't Yet Support an $890 Million Price Tag. Infinite Epigenetics targets a $90 billion U.S. clinical diagnostics market , but the filing offers no revenue or earnings data for the private company. The deal is structured to give Infinite "sufficient capital to scale without additional capital raises" — meaning Nano's cash is the fuel and shareholders bear the dilution.

  • An Activist Investor Is Already Circling. Murchinson Ltd., holding 7.4% of Nano's shares, has been running a proxy campaign to reshape the board , and proposed requiring shareholder approval before any major transaction.

A definitive agreement is expected before July 31, 2026 , setting up a potential showdown vote. If Murchinson rallies enough dissenting shareholders, the deal could stall or collapse — adding yet another layer of uncertainty to a stock already trading at a steep discount to its own cash.